[Oral hypoglycemics and insulin action. Post-receptor effects].
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D005905:Glyburide / Q000494:pharmacology; D006003:Glycogen / Q000096:biosynthesis; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology*; D007333:Insulin Resistance; D007515:Islets of Langerhans / Q000378:metabolism; D008114:Liver Neoplasms, Experimental; D008687:Metformin / Q000494:pharmacology; D051381:Rats; D011972:Receptor, Insulin / Q000187:drug effects*; D014042:Tolazamide / Q000494:pharmacology; D014444:Tyrosine Transaminase / Q000378:metabolism
D007004:Hypoglycemic Agents; D007328:Insulin; D006003:Glycogen; D008687:Metformin; D014042:Tolazamide; D014444:Tyrosine Transaminase; D011972:Receptor, Insulin; D005905:Glyburide
Ipoglicemizzanti orali e azione insulinica. Effetti post-recettoriali.